Lyra Therapeutics to Present at Upcoming Investor Conferences Nov 9, 2022 08:00AM
Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Nov 8, 2022 04:01PM
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 13, 2022 04:01PM
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study Sep 13, 2022 07:00AM
Lyra Therapeutics (LYRA) Presents Additional Phase 2 LANTERN Trial Data Sep 12, 2022 05:44AM
View Older Stories

Sep 10, 2022 08:00AM LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
Sep 8, 2022 07:00AM Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
Sep 6, 2022 07:00AM Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022
Aug 29, 2022 07:00AM Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting
Aug 9, 2022 07:00AM Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 5, 2022 07:02AM Lyra Therapeutics (LYRA) Appoints Richard Nieman as Chief Medical Officer
Jul 5, 2022 07:00AM Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022
Jul 5, 2022 07:00AM Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
Jun 17, 2022 04:01PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 26, 2022 07:00AM Lyra Therapeutics to Present at Upcoming Investor Conferences
May 10, 2022 07:00AM Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022 07:00AM Lyra Therapeutics to Present at Upcoming Investor Conferences
Apr 29, 2022 09:09AM Lyra Therapeutics (LYRA) Reports Positive Data from LANTERN Phase 2 Study of LYR-210
Apr 29, 2022 09:07AM Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
Apr 25, 2022 07:03AM Lyra Therapeutics (LYRA) Doses First Patient in Phase 2 BEACON Trial
Apr 25, 2022 07:00AM Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
Apr 21, 2022 07:00AM Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
Apr 13, 2022 07:00AM Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Mar 9, 2022 07:04AM Lyra Therapeutics (LYRA) Reports Q4; Provides Corporate Update
Mar 9, 2022 07:00AM Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 7, 2022 07:05AM Lyra Therapeutics (LYRA) Appoints Jim Tobin to its Board
Mar 7, 2022 07:00AM Lyra Therapeutics Appoints Jim Tobin to Board of Directors
Feb 28, 2022 07:00AM Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
Feb 17, 2022 07:09AM Lyra Therapeutics (LYRA) Appoints Harlan W. Waksal as Executive Chairman
Feb 17, 2022 07:00AM Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman
Jan 24, 2022 07:00AM Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
Nov 11, 2021 07:00AM Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Nov 9, 2021 04:05PM Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 2, 2021 07:00AM Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9
Oct 19, 2021 07:00AM Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
Oct 4, 2021 07:02AM Lyra Therapeutics (LYRA) Announces New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data
Oct 4, 2021 07:00AM Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Soci
Sep 21, 2021 07:01AM Lyra Therapeutics (LYRA) Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
Sep 21, 2021 07:00AM Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
Sep 21, 2021 07:00AM Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
Sep 20, 2021 07:00AM Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Sep 20, 2021 07:00AM Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Sep 13, 2021 07:02AM Lyra Therapeutics (LYRA) Appoints Jason Cavalier as CFO
Sep 13, 2021 07:00AM Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
Sep 13, 2021 07:00AM Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
Sep 9, 2021 04:05PM Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Sep 9, 2021 04:05PM Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Sep 7, 2021 07:00AM Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 7, 2021 07:00AM Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 17, 2021 07:35AM Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
Aug 17, 2021 07:35AM Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
Aug 9, 2021 04:05PM Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
Aug 9, 2021 04:05PM Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
Jul 26, 2021 04:05PM Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
Jul 26, 2021 04:05PM Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
View Older Stories